×
About 3,703 results

ALLMedicine™ Advanced Prostate Cancer Center

Research & Reviews  1,248 results

Oncolytic adenovirus carrying SPAG9-shRNA enhanced the efficacy of docetaxel for advanc...
https://doi.org/10.1097/CAD.0000000000001251
Anti-cancer Drugs; Lu M, Xu Z et. al.

Sep 26th, 2021 - Sperm-associated antigen 9 (SPAG9) is closely related to the growth and metastasis of advanced prostate cancer. Docetaxel (DTX) is the gold standard for chemotherapy of prostate cancer, but its side effects decrease the life quality of patients. T...

Renal Function Improves After the Discontinuation of Androgen Deprivation Therapy in Ja...
https://doi.org/10.21873/anticanres.15252
Anticancer Research; Masuda H, Fujimoto A et. al.

Sep 4th, 2021 - Androgen deprivation therapy (ADT) is one of the most effective treatments for advanced prostate cancer (PCa). However, it has been reported that the use of ADT is significantly associated with an increased risk of acute kidney injury (AKI) among ...

Repeatability of 68Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
https://doi.org/10.2967/jnumed.121.262528
Journal of Nuclear Medicine : Official Publication, Socie... Seifert R, Sandach P et. al.

Aug 28th, 2021 - Background: Molecular tumor volume (MTV) is a parameter of interest in advanced prostate cancer for assessing total disease burden on prostate specific membrane antigen (PSMA) PET. Although software segmentation tools can delineate whole-body MTV,...

see more →

Guidelines  7 results

ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but...
https://doi.org/10.1016/j.prro.2020.10.002
Practical Radiation Oncology; Zietman AL,

Dec 15th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
https://doi.org/10.1097/JU.0000000000001376
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 23rd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
https://doi.org/10.1097/JU.0000000000001375
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 23rd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...

American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Relate...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB

Sep 7th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|

Optimizing the management of castration-resistant prostate cancer patients: A practical...
https://doi.org/10.1002/pros.24053
The Prostate REFERENCES; Shore ND, Drake CG et. al.

Aug 12th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...

see more →

Drugs  9 results see all →

News  217 results

Common Advanced Prostate Cancer Treatments Not Tied to Significant Cognitive Decline
https://www.medscape.com/viewarticle/955117

Jul 21st, 2021 - (Reuters Health) - Several therapies commonly used to treat men with metastatic castration-resistant prostate cancer don't appear to cause a significant decline in cognitive function, a small study suggests. Researchers examined data on 155 men 65...

Institute of Cancer Research Criticises NICE Rejection of Abiraterone
https://www.medscape.com/viewarticle/954899

Jul 16th, 2021 - The Institute of Cancer Research (ICR) has expressed disappointment at the decision by The National Institute for Health and Care Excellence (NICE) not to approve abiraterone as a first-line treatment for newly diagnosed, advanced prostate cancer....

NICE Publishes Draft Guidance Recommending Enzalutamide for Prostate Cancer
https://www.medscape.com/viewarticle/952659

Jun 8th, 2021 - The National Institute for Health and Care Excellence (NICE) has published draft guidance on the use of the androgen receptor inhibitor enzalutamide (Xtandi, Astellas), plus androgen deprivation therapy (ADT), as an option for treating prostate ca...

Study Shows UK Sniffer Dogs Have a Nose for Prostate Cancer
https://www.medscape.com/viewarticle/946111

Feb 19th, 2021 - The results of a trial led by Medical Detection Dogs in Milton Keynes suggest that trained dogs can detect advanced prostate cancer in urine samples with high specificity and sensitivity. The study, published in  PLoS One,  tested the clinical fea...

Relugolix Confirmed to Cut Menstrual Bleed by Half in Most Women With Fibroids
https://www.medscape.com/viewarticle/945995

Feb 18th, 2021 - (Reuters Health) - Daily relugolix therapy cuts menstrual bleeding by at least half without affecting bone density in 71% of women with uterine fibroids, according to results from the LIBERTY 2 trial, published by The New England Journal of Medici...

see more →